AXGN Insider Trading

Insider Ownership Percentage: 7.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $364,542.50

AxoGen Insider Trading History Chart

This chart shows the insider buying and selling history at AxoGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$500k$0$500kTotal Insider BuyingTotal Insider Selling

AxoGen Share Price & Price History

Current Price: $18.12
Price Change: Price Decrease of -0.385 (-2.08%)
As of 04/1/2025 02:57 PM ET

This chart shows the closing price history over time for AXGN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$18.50Closing price on 03/31/25:

SEC Filings (Institutional Ownership Changes) for AxoGen (NASDAQ:AXGN)

80.29% of AxoGen stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at AXGN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$55Mbought$58MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50M$0$50MTotal InflowsTotal Outflows
AxoGen logo
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
Read More on AxoGen

Today's Range

Now: $18.12
Low: $17.77
High: $18.63

50 Day Range

MA: $18.28
Low: $17.16
High: $20.11

52 Week Range

Now: $18.12
Low: $5.55
High: $21.00

Volume

302,543 shs

Average Volume

421,863 shs

Market Capitalization

$803.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02

Who are the company insiders with the largest holdings of AxoGen?

AxoGen's top insider shareholders include:
  1. Karen L Zaderej (CEO)
  2. Gregory Gene Freitag (Director)
  3. Erick Wayne Devinney (Insider)
  4. Amy Mcbride Wendell (Director)
  5. Guido J Neels (Director)
  6. Peter J Mariani (CFO)
  7. Michael Patrick Donovan (VP)
  8. William P Mr Burke (Director)
Learn More about top insider investors at AxoGen.

Who are the major institutional investors of AxoGen?

AxoGen's top institutional investors include:
  1. First Light Asset Management LLC — 10.24%
  2. Soleus Capital Management L.P. — 6.72%
  3. ArrowMark Colorado Holdings LLC — 5.11%
  4. Geode Capital Management LLC — 2.29%
  5. Driehaus Capital Management LLC — 2.17%
  6. DAFNA Capital Management LLC — 1.92%
Learn More about top institutional investors of AxoGen stock.

Which major investors are selling AxoGen stock?

Within the previous quarter, AXGN stock was sold by these institutional investors:
  1. Millennium Management LLC
  2. Assenagon Asset Management S.A.
  3. Invesco Ltd.
  4. JPMorgan Chase & Co.
  5. Schonfeld Strategic Advisors LLC
  6. D. E. Shaw & Co. Inc.
  7. Tocqueville Asset Management L.P.
  8. Cubist Systematic Strategies LLC
During the last year, company insiders that have sold AxoGen company stock include:
  1. Karen L Zaderej (CEO)
  2. Gregory Gene Freitag (Director)
Learn More investors selling AxoGen stock.

Which major investors are buying AxoGen stock?

In the previous quarter, AXGN stock was bought by institutional investors including:
  1. Driehaus Capital Management LLC
  2. First Light Asset Management LLC
  3. Balyasny Asset Management L.P.
  4. Raymond James Financial Inc.
  5. Raymond James Financial Inc.
  6. Russell Investments Group Ltd.
  7. Ameriprise Financial Inc.
  8. Nicholas Investment Partners LP
Within the previous year, these company insiders have bought AxoGen stock:
  1. Karen L Zaderej (CEO)
  2. Gregory Gene Freitag (Director)
  3. Erick Wayne Devinney (Insider)
Learn More investors buying AxoGen stock.